Clinical features of autoimmune pulmonary alveolar proteinosis from a large international patient cohort: baseline data from the IMPALA trial
B. Trapnell (Cincinnati, United States of America), C. Ganslandt (Austin, United States of America), I. Tarnow (Austin, United States of America), T. Jouhikainen (Austin, United States of America), G. Waterer (Perth, Australia), C. Morgan (London, United Kingdom)
Source: International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives
Disease area: Airway diseases, Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Trapnell (Cincinnati, United States of America), C. Ganslandt (Austin, United States of America), I. Tarnow (Austin, United States of America), T. Jouhikainen (Austin, United States of America), G. Waterer (Perth, Australia), C. Morgan (London, United Kingdom). Clinical features of autoimmune pulmonary alveolar proteinosis from a large international patient cohort: baseline data from the IMPALA trial. 5328
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: